Effective Feb 24, 2021, Genopis is part of the WACKER family, which expands WACKER’s global biotech footprint and provides a foundation for commercialization and further growth of Genopis’ innovations. Check out WACKER’s website to learn more about the company’s biopharma business.
Genopis, Inc. was established in August 2018 through a joint venture partnership by Helixmith (formerly ViroMed) and a private equity firm, and the company was acquired by WACKER in February 2021. The company is headquartered in San Diego, California and the facility serves as the site for cGMP manufacturing operations, with currently capabilities suited for microbial-based products and expandable for future mammalian-based products. Genopis specializes in plasmid DNA based technology and provides contract development and manufacturing organization (CDMO) opportunities to help your company reach its clinical and commercial goals.
The company is supported by staff members who have several decades of experience ranging from clinical start-up to commercial product companies. With our experience, our team provides the flexibility to transition rapidly in a fast-paced biotechnology environment and achieve the end goal, which is to provide medicine for our clients’ patients.
Provide services and products that meet the highest quality and compliance standards.